IL1B and systemic-onset juvenile idiopathic arthritis: This is a central point highlighting the possibility to decrease the immunosuppressant load in patients with Still’s disease, which is essential to reduce adverse events, previously described more frequent in patients administered with IL-1 antagonists and a concomitant cDMARD (36).